Market Overview

At 10:08 AM Central Europe on Monday 26 November 2026, shares of Century Therapeutics (IPSC) fell 7.59 % over the preceding 24 hours, closing at approximately USD 1.46 per share. The decline reflects a broader trend that has seen the company’s valuation slip by 13.61 % since the end of last month.

With a market capitalisation of USD 264.4 million and a circulating supply of 181.1 million shares, the stock has been traded in the last 24 hours for a modest USD 1.3 million of volume. The 200‑day simple moving average sits at USD 2.11, underscoring the recent downward drift from the peak of USD 3.04 reached on 3 October 2026, to the 52‑week low of USD 0.44 recorded on 17 November 2025.

Comparative Performance

Other biopharmaceutical and acquisition‑focused stocks have posted relatively muted movements in the same period:

  • Abony Acquisition I (AACO): Flat at USD 10.02, unchanged, with a market capitalisation of USD 313.6 million.
  • Legato Merger IV (LEGO): Down 0.1 % to USD 9.98, market capitalisation USD 312.4 million.
  • Contineum Therapeutics (CTNM): Down 1.01 % to USD 8.31, market capitalisation USD 312.6 million.
  • Safeguard Acquisition C (SAC): Down 0.2 % to USD 10.09, market capitalisation USD 316.5 million; price‑earnings ratio 327.56.
  • Cambridge Acquisition (CAQ): Down 0.5 % to USD 10.00, market capitalisation USD 313.2 million.

These figures suggest that while the broader sector remains largely stable, Century Therapeutics is experiencing a sharper pullback that could be tied to recent developments in its research pipeline or investor sentiment.

Company Context

Century Therapeutics, Inc. is a biotechnology firm headquartered in the United States and listed on the Nasdaq. Its core competency lies in the development of adult stem‑cell‑based therapies aimed at producing curative cell‑therapy products for cancer. The company’s global customer base and its focus on cutting‑edge regenerative medicine position it within a rapidly evolving therapeutic landscape. Investors may find the recent price volatility noteworthy as the firm continues to navigate the complexities of bringing novel cell‑therapy products from laboratory to market.

For further information, stakeholders can visit the company’s website at www.centurytx.com .